Lake Street Private Wealth LLC Buys 29,721 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Lake Street Private Wealth LLC boosted its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 28.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 133,168 shares of the company’s stock after buying an additional 29,721 shares during the period. Lake Street Private Wealth LLC’s holdings in Hims & Hers Health were worth $3,220,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in HIMS. Carnegie Investment Counsel grew its stake in shares of Hims & Hers Health by 25.5% in the fourth quarter. Carnegie Investment Counsel now owns 376,910 shares of the company’s stock worth $9,114,000 after acquiring an additional 76,650 shares during the last quarter. CHURCHILL MANAGEMENT Corp purchased a new position in shares of Hims & Hers Health in the 4th quarter worth about $445,000. Cadent Capital Advisors LLC boosted its stake in Hims & Hers Health by 1.5% in the 4th quarter. Cadent Capital Advisors LLC now owns 72,160 shares of the company’s stock worth $1,745,000 after purchasing an additional 1,060 shares in the last quarter. GAMMA Investing LLC grew its position in Hims & Hers Health by 2,173.7% during the 4th quarter. GAMMA Investing LLC now owns 2,251 shares of the company’s stock valued at $54,000 after purchasing an additional 2,152 shares during the last quarter. Finally, Principal Financial Group Inc. increased its stake in Hims & Hers Health by 102.0% during the 3rd quarter. Principal Financial Group Inc. now owns 290,414 shares of the company’s stock valued at $5,349,000 after purchasing an additional 146,621 shares in the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Trading Down 0.5 %

Shares of HIMS stock opened at $27.80 on Friday. The company has a 50 day simple moving average of $27.68 and a two-hundred day simple moving average of $21.85. The stock has a market cap of $6.07 billion, a P/E ratio of 63.19 and a beta of 1.31. Hims & Hers Health, Inc. has a 12 month low of $8.14 and a 12 month high of $35.02.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, November 4th. The company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.26. The company had revenue of $401.56 million for the quarter, compared to analysts’ expectations of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. Hims & Hers Health’s revenue for the quarter was up 77.1% compared to the same quarter last year. During the same period last year, the firm earned ($0.04) EPS. As a group, equities analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. TD Cowen reiterated a “buy” rating and issued a $28.00 target price on shares of Hims & Hers Health in a research note on Wednesday, November 20th. BTIG Research initiated coverage on Hims & Hers Health in a research report on Tuesday, January 7th. They issued a “buy” rating and a $35.00 price objective on the stock. Canaccord Genuity Group increased their target price on Hims & Hers Health from $28.00 to $38.00 and gave the company a “buy” rating in a research note on Monday, December 2nd. Deutsche Bank Aktiengesellschaft boosted their price target on Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research note on Wednesday, November 6th. Finally, Needham & Company LLC increased their price objective on Hims & Hers Health from $28.00 to $31.00 and gave the company a “buy” rating in a research report on Monday, January 6th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, Hims & Hers Health presently has an average rating of “Hold” and an average price target of $25.13.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, insider Michael Chi sold 17,304 shares of Hims & Hers Health stock in a transaction that occurred on Friday, October 25th. The shares were sold at an average price of $22.00, for a total transaction of $380,688.00. Following the transaction, the insider now owns 193,980 shares of the company’s stock, valued at $4,267,560. The trade was a 8.19 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Soleil Boughton sold 2,339 shares of the company’s stock in a transaction that occurred on Tuesday, October 29th. The stock was sold at an average price of $23.16, for a total transaction of $54,171.24. Following the completion of the transaction, the insider now owns 169,935 shares of the company’s stock, valued at approximately $3,935,694.60. The trade was a 1.36 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,080,208 shares of company stock valued at $29,106,823 over the last quarter. 17.71% of the stock is currently owned by company insiders.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.